Focal segmental glomerulosclerosis secondary to subcutaneous interferon β-1a treatment in a patient with multiple sclerosis

Leticia Tornes; Silvia Delgado; Monica Garcia-Buitrago; Melissa R Ortega; Kottil W Rammohan

doi:10.1016/j.msard.2012.02.002

Focal segmental glomerulosclerosis secondary to subcutaneous interferon β-1a treatment in a patient with multiple sclerosis

Mult Scler Relat Disord. 2012 Jul;1(3):148-51. doi: 10.1016/j.msard.2012.02.002. Epub 2012 Mar 14.

Authors

Leticia Tornes¹, Silvia Delgado², Monica Garcia-Buitrago³, Melissa R Ortega⁴, Kottil W Rammohan⁵

Affiliations

¹ University of Miami Miller School of Medicine, Department of Neurology, 1120 NW 14 Street, 13th Floor, Miami, FL 33136, USA. Electronic address: ltornes@med.miami.edu.
² University of Miami Miller School of Medicine, Department of Neurology, 1120 NW 14 Street, 13th Floor, Miami, FL 33136, USA. Electronic address: Sdelgado1@med.miami.edu.
³ University of Miami Miller School of Medicine, Department of Pathology, 1611 NW 12 Ave Holtz Building, #2042, USA. Electronic address: Mgarcia22@med.miami.edu.
⁴ University of Miami Miller School of Medicine, Department of Neurology, 1120 NW 14 Street, 13th Floor, Miami, FL 33136, USA. Electronic address: Mortega2@med.miami.edu.
⁵ University of Miami Miller School of Medicine, Department of Neurology, 1120 NW 14 Street, 13th Floor, Miami, FL 33136, USA. Electronic address: Krammohan@med.miami.edu.

PMID: 25877082
DOI: 10.1016/j.msard.2012.02.002

Abstract

Interferon (IFN)-β is a first line treatment for patients with relapsing remitting multiple sclerosis (RRMS) that has been shown to decrease relapse rates, reduce magnetic resonance imaging (MRI) disease burden and possibly delay onset of disability (Arnason, 2005). There are few reports of nephrotic syndrome related to Minimal Change Disease (MCD) or Focal Segmental Glomerulosclerosis (FSGS) during treatment with IFN-α (Nishimura et al., 2002; Tola et al., 2003; Rettmar et al., 1995). There are fewer reports of nephrotic syndrome induced by IFN-β (Tola et al., 2003; Auty and Saleh, 2005; Kumasaka et al., 2006). We report a 41 year old African American woman with RRMS that developed FSGS after 3 months of treatment with IFN-β-1a 3 times weekly and review the previously published cases.

Keywords: Adverse effects; Focal segmental glomerulosclerosis; Glomerulonephritis; Interferon beta; Kidney failure; Multiple sclerosis.